AbCellera Biologics announced the pricing of an underwritten public offering expected to generate gross proceeds of approximately $200 million. The company plans to use the net proceeds to fund research, development, and the clinical advancement of its internal pipeline, including its lead program ABCL635, as well as for general corporate purposes.
Key Details
- Offering Terms: The offering consists of 17,435,897 common shares priced at $9.75 per share, and pre-funded warrants to purchase an additional 3,076,926 common shares.
- Financial Impact: Expected gross proceeds are approximately $200 million, with estimated net proceeds of $187 million after deducting underwriting discounts and other expenses.
- Timeline: The company entered into the underwriting agreement on August 12, 2026, and the offering is expected to close on or about August 14, 2026.